Three months after Japanese pharmaceutical company Daiichi Sankyo purchased a US$5.4 billion controlling stake in Indian generic drug manufacturer Ranbaxy, the Japanese company announced that it would write down the purchase. The company has reported a valuation loss of US$3.97 billion on the deal, based on the closing price of Ranbaxy shares on 31 December, according to comments made by spokesman Satoro Ogawa to Bloomberg.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
